Asthika Goonewardene
Leerink Partners has expanded its healthcare research platform with the appointment of Asthika Goonewardene as Senior Managing Director and Senior Research Analyst covering oncology, reinforcing the firm’s focus on one of the fastest-evolving segments of the biotechnology industry.
Goonewardene joins the healthcare-focused investment bank with nearly two decades of biotechnology research experience and will be based in the firm’s Miami office. He will report to Jim Kelly, Director of Equity Research, and will lead coverage of publicly traded oncology companies and emerging cancer treatment technologies.
The hire comes as oncology remains one of the most active areas for biotechnology investment, driven by advances in immuno-oncology, cell therapy, precision medicine, and next-generation therapeutic platforms. Investors continue to closely monitor the sector as companies pursue novel approaches to treating cancer and seek to differentiate themselves in an increasingly competitive landscape.
“Asthika is a highly respected biotechnology analyst with a strong track record of identifying emerging trends and providing differentiated insights across the oncology landscape,” Kelly said. “As innovation in cancer therapeutics continues to accelerate, his deep scientific understanding, extensive network of key opinion leaders, and sector expertise will further strengthen our research platform and enhance the value we provide to institutional investors and corporate clients.”
Goonewardene joins Leerink from Truist Securities, where he served as Managing Director and Senior Biotechnology Analyst. Prior to that, he was a Senior Biotechnology Analyst at Bloomberg Intelligence, leading coverage of the global biotechnology sector and providing research on emerging scientific developments, clinical programs, and industry trends.
Earlier in his career, he held research and consulting positions focused on biotechnology innovation and pharmaceutical development, building expertise across multiple therapeutic categories and stages of the drug development process.
At Leerink, Goonewardene will focus on cancer therapeutics, immuno-oncology, cell therapy, and emerging biotechnology platforms, providing research and analysis designed to help institutional investors evaluate opportunities and risks within the sector. His coverage is expected to span both established biotechnology companies and emerging innovators developing next-generation treatments.
“Leerink Partners has built the industry’s premier healthcare research platform and a reputation for delivering high-quality, differentiated insights to investors,” Goonewardene said. “I am excited to join the Firm’s talented research team and help clients navigate one of the most innovative and rapidly evolving periods in oncology.”
The addition reflects continued investment by healthcare-focused financial institutions in specialized research capabilities as scientific innovation reshapes the biotechnology landscape. Advances in cancer treatment, including targeted therapies, cellular therapies, and immune-based approaches, have increased demand for analysts capable of interpreting complex clinical data and assessing commercial potential.
For investment banks serving healthcare companies and institutional investors, research expertise has become an increasingly important differentiator as biotechnology firms seek capital, strategic advice, and market intelligence throughout the development lifecycle.
Leerink Partners specializes exclusively in healthcare and has built a reputation for providing advisory services, capital markets expertise, and research across biotechnology, pharmaceuticals, medical technology, healthcare services, and related sectors. Since its founding, the firm has advised on approximately $85 billion in transactions and helped clients raise more than $220 billion in capital.
With the addition of Goonewardene, Leerink continues to deepen its oncology research capabilities at a time when scientific breakthroughs and investor interest are driving significant activity across the global biotechnology market.
